{
    "address": "Tomtebodavagen 23A",
    "city": "Solna",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W95637117",
    "description": "Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The company is headquartered in Solna, Stockholm and currently employs 1,508 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company\u2019s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.",
    "employeeTotal": "1508.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2006-09-15",
    "isin": "SE0000872095",
    "logo": "",
    "marketCapitalization": 52104.36,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Swedish Orphan Biovitrum AB (publ)",
    "phone": "4686972000.0",
    "sedol": "B1CC9H0",
    "shareOutstanding": 295.144629,
    "state": "STOCKHOLM",
    "ticker": "SOBI.ST",
    "weburl": "https://www.sobi.com/"
}